Sensex: 36051.81 Gold: 49062 Covid-19 New Cases: 32676
Phase-1 clinical trials of India's Covaxin
- Bharat Biotech's Covid-19 vaccine candidate Covaxin registered a robust immune response in the Phase 1 clinical trials
- Covaxin had received approval of drug regulator DCGI for phase I and II of human clinical trials
- Bharat Biotech worked closely with ICMR to bring the vaccine for general public